These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16216515)

  • 21. Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators.
    Pettersson M; Johnson DS; Subramanyam C; Bales KR; am Ende CW; Fish BA; Green ME; Kauffman GW; Lira R; Mullins PB; Navaratnam T; Sakya SM; Stiff CM; Tran TP; Vetelino BC; Xie L; Zhang L; Pustilnik LR; Wood KM; O'Donnell CJ
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2906-11. PubMed ID: 22429469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
    Dang Q; Kasibhatla SR; Reddy KR; Jiang T; Reddy MR; Potter SC; Fujitaki JM; van Poelje PD; Huang J; Lipscomb WN; Erion MD
    J Am Chem Soc; 2007 Dec; 129(50):15491-502. PubMed ID: 18041834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors.
    Cheng XC; Wang Q; Fang H; Tang W; Xu WF
    Eur J Med Chem; 2008 Oct; 43(10):2130-9. PubMed ID: 18362041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    J Med Chem; 2014 Nov; 57(21):8886-902. PubMed ID: 25264600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
    Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.
    Shiozaki M; Maeda K; Miura T; Kotoku M; Yamasaki T; Matsuda I; Aoki K; Yasue K; Imai H; Ubukata M; Suma A; Yokota M; Hotta T; Tanaka M; Hase Y; Haas J; Fryer AM; Laird ER; Littmann NM; Andrews SW; Josey JA; Mimura T; Shinozaki Y; Yoshiuchi H; Inaba T
    J Med Chem; 2011 Apr; 54(8):2839-63. PubMed ID: 21417219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases.
    Hu LY; Boxer PA; Kesten SR; Lei HJ; Wustrow DJ; Moreland DW; Zhang L; Ahn K; Ryder TR; Liu X; Rubin JR; Fahnoe K; Carroll RT; Dutta S; Fahnoe DC; Probert AW; Roof RL; Rafferty MF; Kostlan CR; Scholten JD; Hood M; Ren XD; Schielke GP; Su TZ; Taylor CP; Mistry A; McConnell P; Hasemann C; Ohren J
    Bioorg Med Chem Lett; 2006 May; 16(9):2337-40. PubMed ID: 16143519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.
    De Savi C; Morley AD; Nash I; Karoutchi G; Page K; Ting A; Gerhardt S
    Bioorg Med Chem Lett; 2012 Jan; 22(1):271-7. PubMed ID: 22153941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and activity of selective MMP inhibitors with an aryl backbone.
    Barta TE; Becker DP; Bedell LJ; De Crescenzo GA; McDonald JJ; Munie GE; Rao S; Shieh HS; Stegeman R; Stevens AM; Villamil CI
    Bioorg Med Chem Lett; 2000 Dec; 10(24):2815-7. PubMed ID: 11133099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis.
    Janusz MJ; Hookfin EB; Brown KK; Hsieh LC; Heitmeyer SA; Taiwo YO; Natchus MG; Pikul S; Almstead NG; De B; Peng SX; Baker TR; Patel V
    Inflamm Res; 2006 Feb; 55(2):60-5. PubMed ID: 16612565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.
    Xu J; Wei L; Mathvink R; Edmondson SD; Mastracchio A; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Petrov A; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1346-9. PubMed ID: 16332437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6.
    Shimamura K; Nagumo A; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Morita N; Ohe T; Takahashi T; Nagase T; Sato N; Tokita S
    Eur J Pharmacol; 2010 Mar; 630(1-3):34-41. PubMed ID: 20045404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors.
    Xiang Y; Hirth B; Asmussen G; Biemann HP; Bishop KA; Good A; Fitzgerald M; Gladysheva T; Jain A; Jancsics K; Liu J; Metz M; Papoulis A; Skerlj R; Stepp JD; Wei RR
    Bioorg Med Chem Lett; 2011 May; 21(10):3050-6. PubMed ID: 21507633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.
    Kolodziej SA; Hockerman SL; DeCrescenzo GA; McDonald JJ; Mischke DA; Munie GE; Fletcher TR; Stehle N; Swearingen C; Becker DP
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3561-4. PubMed ID: 20529685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
    Noe MC; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4727-30. PubMed ID: 15324896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and identification of conformationally constrained selective MMP inhibitors.
    Freskos JN; McDonald JJ; Mischke BV; Mullins PB; Shieh HS; Stegeman RA; Stevens AM
    Bioorg Med Chem Lett; 1999 Jul; 9(13):1757-60. PubMed ID: 10406637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV.
    Duffy JL; Kirk BA; Wang L; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 May; 17(10):2879-85. PubMed ID: 17350841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia.
    Ho GD; Yang SW; Smotryski J; Bercovici A; Nechuta T; Smith EM; McElroy W; Tan Z; Tulshian D; McKittrick B; Greenlee WJ; Hruza A; Xiao L; Rindgen D; Mullins D; Guzzi M; Zhang X; Bleickardt C; Hodgson R
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1019-22. PubMed ID: 22222034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase.
    Eldrup AB; Soleymanzadeh F; Taylor SJ; Muegge I; Farrow NA; Joseph D; McKellop K; Man CC; Kukulka A; De Lombaert S
    J Med Chem; 2009 Oct; 52(19):5880-95. PubMed ID: 19746975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: Methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquinazolin-6-ylmethylcarbamate (CKD 533).
    Choi H; Lee J; Kim YH; Im DS; Hwang IC; Kim SJ; Moon SK; Lee HW; Lee SS; Ahn SK; Kim SW; Choi NS; Lee KJ
    Bioorg Med Chem Lett; 2010 Jan; 20(1):383-6. PubMed ID: 19906530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.